<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: This study aims to evaluate the efficacy and safety of adding <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> to treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> (MF) and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>) who had inadequate glycemic control </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This study is a retrospective cohort study based on King Abdullah University Hospital records concerning type 2 diabetic adult patients for year 2008 </plain></SENT>
<SENT sid="2" pm="."><plain>Patients included were assessed according to changes in glycosylated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (HbA1c), <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, <z:mp ids='MP_0002871'>albuminuria</z:mp> and liver enzymes before and after the addition of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The patients included in the study had an initial mean HbA1c of 9.44%, which decreased to 7.56% after the addition of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (P-value &lt; 0.005) </plain></SENT>
</text></document>